Skip to main content

Table 4 Independent predictors for the achievement of LDA at 24 weeks in multivariable analysis

From: Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

 

Tofacitinib

Baricitinib

Variables

Univariate model

Multivariable model

Univariate model

Multivariable model

OR (95% CI)

P value

OR (95% CI)

P value

OR (95% CI)

P value

OR (95% CI)

P value

Age (per 1-year increase)

0.997 (0.969–1.026)

0.838

–

 

0.987 (0.951–1.023)

0.462

–

 

Disease duration (per 1-year increase)

0.999 (0.965–1.034)

0.944

–

 

0.965 (0.919–1.014)

0.153

–

 

Concomitant MTX use (yes/no)

1.02 (0.499–2.085)

0.957

–

 

1.869 (0.770–4.535)

0.165

–

 

Concomitant oral steroid use (yes/no)

0.403 (0.203–0.799)

0.008*

0.470 (0.232–0.953)

0.035*

0.412 (0.167–1.013)

0.050

0.339 (0.102–1.129)

0.073

Number of previous use of b/tsDMARDs (per drug)

0.882 (0.714–1.09)

0.240

–

 

0.687 (0.522–0.905)

0.005*

0.700 (0.504–0.971)

0.026*

Inadequate response of another JAK inhibitor (yes/no)

    

0.511 (0.194–1.341)

0.167

–

 

DAS28-ESR at baseline (per 1 increase)

0.798 (0.628–1.014)

0.061

0.882 (0.678–1.147)

0.345

0.395 (0.247–0.633)

< 0.001*

0.395 (0.225–0.694)

< 0.001*

mHAQ (per 1 increase)

0.603 (0.366–0.996)

0.039*

0.745 (0.424–1.304)

0.294

0.322 (0.155–0.667)

< 0.001*

0.697 (0.301–1.611)

0.396

ACPA positive (yes/no)

1.286 (0.568–2.912)

0.543

–

 

0.426 (0.138–1.314)

0.131

–

 

RF positive (yes/no)

1.687 (0.733–3.886)

0.207

–

 

0.429 (0.115–1.599)

0.198

–

 
  1. OR odds ratio, 95% CI 95% confidence interval, MTX methotrexate, b/tsDMARDs biological and/or targeted synthetic disease-modifying antirheumatic drugs, JAK Janus kinase, DAS disease activity score, mHAQ modified Health Assessment Questionnaire, ESR erythrocyte sedimentation rate, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor
  2. *P < 0.05